De patienter, der fik docetaxel hver 3. uge, viste signifikant længere total overlevelsese sammenlignet med dem, der fik mitoxantrone.
Patients who received docetaxel every three weeks demonstrated significantly longer overall survival compared to those treated with mitoxantrone.